Keynote 158

KEYNOTE-158 is an international, open-label, multicohort phase II study of pembrolizumab monotherapy in multiple advanced solid tumor types that have progressed with standard-of-caresystemictherapy.Keyeligibilitycriteriafor the cervical cancer cohort included age $ 18 years, his-

Keynote 158. KEYNOTE-158 (NCT02628067) is a phase 2 basket study that includes patients with malignant pleural mesothelioma and is designed to assess biomarkers that are predictive of response to pembrolizumab as second-line therapy; another phase 2 study is also exploring pembrolizumab as a first-line agent in comparison with standard of care cisplatin. Pembrolizumab, an anti‒programmed death-1 monoclonal antibody, has antitumor activity against MSI-H/dMMR cancer. We report data from the phase II KEYNOTE-158 study of pembrolizumab in patients with previously treated, advanced noncolorectal MSI-H/dMMR cancer. keynote-158研究同时也纳入了部分宫颈癌患者，该研究前期82例患者的数据分析结果与keynote-028研究一致，确认了帕博利珠单抗单药治疗晚期宫颈癌的疗效。keynote-158研究本次分析尝试去探索全部98例经治晚期宫颈癌患者中帕博利珠单抗单药的有效性和安全性。 目的 KEYNOTE-158. The recent publication in the Journal of Clinical Oncology reported on a cohort of 98 adult patients with previously treated advanced cervical cancer of phase II KEYNOTE-158 (NCT02628067) basket trial in multiple types of solid tumours.Eligible patients in the cervical cancer cohort were ≥ 18 years old with histologically or cytologically confirmed advanced cervical cancer and.

"KEYNOTE-158 has confirmed clinical activity of pembrolizumab in tumors harboring a TMB ≥10 across a variety of solid tumors including anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small cell lung, thyroid, and vulvar cancers." Adverse reactions occurring in patients with TMB‑H cancer enrolled in KEYNOTE-158 were similar to those occurring in patients with other solid tumors who received pembrolizumab as a single agent. Introduction: Pembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067).We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC. 8506 Background: The antitumor activity of pembrolizumab, an IgG4 anti-PD-1 monoclonal antibody, was evaluated in patients (pts) with SCLC in KEYNOTE-158 (NCT02628067), a phase 2 basket study of 11 cancer types. Methods: Enrolled pts were aged ≥18 y with advanced SCLC; had measurable disease per RECIST v1.1; ECOG PS ≤1; incurable disease with prior failure of, progression on, or.

KEYNOTE-158 enrolled 233 patients with MSI-H/dMMR noncolorectal cancer, which represents the largest cohort of this type treated with an immunotherapy agent to our knowledge. A broad range of solid tumors were represented in the study population with the most common being endometrial cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer. Adverse reactions occurring in patients with TMB‑H cancer enrolled in KEYNOTE-158 were similar to those occurring in patients with other solid tumours who received pembrolizumab as a single agent. The most common adverse reactions to pembrolizumab are fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhoea, nausea, rash. Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab (Keytruda) in patients with advanced. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Sep 10. pii: S1470-2045(20)30445-9. doi: 10.1016/S1470-2045(20)30445-9. [Epub ahead of print]

MSI-H is expressed in ∼25% of endometrial cancers. An analysis of pts with MSI-H advanced endometrial cancer enrolled in cohorts D (advanced endometrial cancer) and K (pan-tumor MSI-H) of the phase 2 KEYNOTE-158 basket study (NCT02628067) is presented. Methods About KEYNOTE-158 KEYNOTE-158 ( NCT02628067 ) is a multicenter, multi-cohort, non-randomized, open-label trial evaluating KEYTRUDA (200 mg every three weeks) in patients with solid tumors. PURPOSE KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from patients with previously treated advanced cervical cancer. PATIENTS AND METHODS Patients received pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable. Purpose: KEYNOTE-158 (ClinicalTrials.gov identifier: [NCT02628067][1]) investigated the efficacy and safety of pembrolizumab across multiple cancers. We present results from patients with previously treated advanced well-differentiated neuroendocrine tumors (NET). Patients and Methods: Pembrolizumab 200 mg was administered every 3 weeks for 2 years or until progression, intolerable toxicity.

The KEYNOTE-158, phase II study investigated efficacy of pembrolizumab in patients with previously treated, advanced non-colorectal MSI-H/dMMR cancers. The primary endpoint was objective response rate (ORR) per RECIST v1.1, as assessed by independent central radiologic review. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. Prof Hyun Cheol Chung speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from the KEYNOTE-028 and KEYNOTE-158 studies looking at Pembrolizumab as treatment for advanced small-cell lung cancer (SCLC) after two or more lines of prior therapy. Prof Chung reports that in KEYNOTE-028 patients were PD-L1 positive and the response rate seen was around 30%. Purpose: KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types.We present interim results from patients with previously treated advanced cervical cancer. Patients and methods: Patients received pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable.

Pembrolizumab was given at 10 mg/kg every 2 weeks in KEYNOTE-028 versus a dose of 200 mg given every 3 weeks in KEYNOTE-158. In both trials, the agent was administered for the duration of 2 years.